Vorsetuzumab mafodotin (original) (raw)

Vorsetuzumab mafodotin (SGN-75) is an antibody-drug conjugate (ADC) directed to the protein CD70 designed for the treatment of cancer. It is a humanized monoclonal antibody, vorsetuzumab, conjugated with noncleavable monomethyl auristatin F (MMAF), a cytotoxic agent. This drug was developed by Seattle Genetics, Inc. The drug completed phase I clinical trials for renal cell carcinoma, but development was discontinued in 2013. No reason was given but SG plan to start clinical trials of in 2014.